Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 Diabetes

Chiara Dalla Man, Gerlies Bock, Paula D. Giesler, Denise B. Serra, Monica Ligueros Saylan, James E. Foley, Michael Camilleri, Gianna Toffolo, Claudio Cobelli, Robert A. Rizza, Adrian Vella

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Objective-The purpose of this study was to determine the mechanism by which dipep-tidyl peptidase-4 inhibitors lower postprandial glucose concentrations. Research design and methods- We measured insulin secretion and action as well as glucose effectiveness in 14 subjects with type 2 diabetes who received vildagliptin (50 mg b.i.d.) or placebo for 10 days in random order separated by a 3-week washout. On day 9 of each period, subjects ate a mixed meal. Insulin sensitivity (SI), glucose effectiveness, and β-cell responsivity indexes were estimated using the oral glucose and C-peptide minimal models. At 300 min 0.02 unit/kg insulin was administered intravenously. Results- Vildagliptin reduced postprandial glucose concentrations (905 ± 94 vs. 1,008 ± 104 mmol/6 h, P = 0.02). Vildagliptin did not alter net S I (7.71 ± 1.28 vs. 6.41 ±0.84 10-4 dl · kg-1 · min-1 · (μU-1 · ml-1,P= 0.13) or glucose effectiveness (0.019 ± 0.002 vs. 0.018 ± 0.002 dl · kg-1 · min -1,P= 0.65). However, the net β-cell responsivity index was increased (35.7 ± 5.2 vs. 28.9 ± 5.2 10-9 min -1, P= 0.03) as was total disposition index (381 ± 48 vs. 261 ±35 10-14dl. kg-1 ·min -2-pmol-1 *l-1, P=0.006). Vildagliptin lowered postprandial glucagon concentrations (27.0 ±1.1 vs. 29.7 ± 1.5 (xg · l-1 · 6 h-1, P= 0.03), especially after administration of exogenous insulin (81.5 ± 6.4vs. 99.3 ± 5.6ng/l,P= 0.02). Conclusions-Vildagliptin lowers postprandial glucose concentrations by stimulating insulin secretion and suppressing glucagon secretion but not by altered insulin action or glucose effectiveness. A novel observation is that vildagliptin alters a-cell responsiveness to insulin administration, but the significance of this action is as yet unclear.

Original languageEnglish (US)
Pages (from-to)14-18
Number of pages5
JournalDiabetes care
Issue number1
StatePublished - Jan 2009

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing


Dive into the research topics of 'Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 Diabetes'. Together they form a unique fingerprint.

Cite this